Premature Infant Drug Curosurf Suspected of Contamination; FDA Issues Red Alert for Recall

AI Summary (NQ-processed)

Taiwan's Food and Drug Administration (FDA) issued a red alert for the premature infant drug "Curosurf Inhalation Suspension" due to reported microbial contamination risks from the Czech Republic and Italy for similar products manufactured by CHIESI FARMACEUTICI S.P.A. The Taiwanese importer, Hualien Biotech Pharmaceutical Co., Ltd., has initiated a precautionary recall, aiming to complete the recall of 70 bottles by April 24th and submit an investigation report. The FDA assures that current stock is sufficient, with no risk of drug shortage.